After JPM 2026: Where Healthcare Strategy Is Actually Heading

By Vlad Bogin, MD, FACP
CEO, Cromos Pharma

The J.P. Morgan Healthcare Conference has always been a defining moment for the healthcare industry, not because of a single announcement, but because of the collective direction that emerges once the week is over. JPM 2026 followed that pattern, but with a noticeable shift in tone. This was not a conference about resurgence or recovery. It was about recalibration.

The industry is no longer asking how to survive a downturn. It is asking how to build growth that holds up under scrutiny. Below are the signals from JPM 2026 that, in my view, will shape healthcare strategy and clinical development decisions in the year ahead.

The Market Is Still Buying, Just Not Speculation

JPM 2026 unfolded without a wave of headline biopharma mega-deals, reinforcing a more restrained tone around large-scale acquisitions. That restraint, however, did not reflect a lack of capital or strategic intent. Instead, it highlighted where sizable transactions are still being executed.

Medtech stood out as the segment where large deals continue to materialize, exemplified by Boston Scientific’s $14.5 billion acquisition of Penumbra, a transaction anchored in predictable reimbursement, clear regulatory positioning, and integration-ready platforms. The takeaway was not that M&A appetite has weakened, but that capital is concentrating where execution risk is lower and commercialization is more visible. JPM 2026 underscored a growing bifurcation: medtech currently offers a more defensible near-term return profile than most early-stage biopharma assets.

Targeted Business Development Is Replacing Transformational Acquisitions

Instead of large takeovers, JPM 2026 highlighted a preference for precise, capability-driven transactions. Novartis pointed to targeted licensing activity, including radioligand-related assets sourced from China. AstraZeneca’s acquisition of an AI-focused partner reinforced the same logic: acquiring specific capabilities that strengthen existing pipelines rather than absorbing entire organizations.

This shift signals a broader move toward modular growth. Companies are filling defined gaps, not rewriting their balance sheets.

Capital Discipline Is Now Openly Part of the Growth Narrative

Multiple CEOs used their JPM platforms to speak directly about cost control, balance-sheet resilience, and operational focus. Moderna framed 2026 as a year of financial stabilization, narrowing its cost base while using respiratory vaccines as a cash engine to fund oncology and rare disease programs. Genmab similarly emphasized sustained, long-term value creation over near-term expansion.

These were not defensive messages. They were signals that capital efficiency has become central to valuation and investor confidence.

GLP-1: From Clinical Leadership to Execution at Scale

GLP-1 therapies were discussed at JPM 2026 less as a scientific race and more as an execution challenge. Market leaders Novo Nordisk and Eli Lilly and Company focused on manufacturing scale, supply reliability, and direct-to-consumer access rather than marginal efficacy differences.

A recurring theme was that 2026 is the “year of the pill.” Oral GLP-1 formulations were positioned as the next growth lever, particularly for needle-averse patients and markets without cold-chain infrastructure. The implication was clear: in GLP-1, operational readiness now matters more than incremental scientific differentiation.

AI Has Moved from Innovation Headline to Execution Infrastructure

Artificial intelligence was everywhere at JPM 2026, but no longer as a headline. It was discussed as core infrastructure. A clear example was the announcement by NVIDIA and Eli Lilly and Company of a co-innovation AI lab, backed by a multi-year investment of up to $1 billion, aimed at embedding advanced compute and AI models directly into drug discovery and development workflows to accelerate timelines.

Across the conference, AI was framed as an execution tool. Its value was defined by concrete outcomes: faster development timelines, better data quality, reduced risk, and quicker decision-making in clinical programs.

Oncology Strategies Are Being Built Around Platforms and Combinations

Oncology remained the dominant therapeutic focus, but the framing has clearly evolved. Roche used JPM to reinforce a strategy centered on integrating therapeutics with diagnostics and strategic partnerships, rather than promoting single-asset stories. BioNTech emphasized its transition toward a multiproduct oncology company built on combination strategies and late-stage execution.

Across companies, the message was consistent. Platform depth, combinability, and lifecycle optionality now matter more than isolated breakthroughs.

Generics and Biosimilars Are Being Repositioned as Growth Engines

Sandoz provided one of the clearest examples of how traditionally “non-innovative” segments are being reframed. Its leadership described the coming decade as a structural opportunity driven by widespread loss of exclusivity. Investments in biosimilars manufacturing and antibiotics were presented not as defensive cost plays, but as strategic growth initiatives tied to access, resilience, and scale.

This reframing resonated strongly with investors and reflects a broader redefinition of innovation in healthcare.

Asia Is an Active Source of Innovation and Partnerships

China’s presence at JPM 2026 was impossible to ignore. Despite ongoing geopolitical tension, cross-border licensing and partnerships continued. Deals involving Chinese-origin assets reinforced a clear reality: innovation sourcing has become geography-agnostic. Large sponsors are prioritizing differentiated science wherever it originates, while simultaneously diversifying manufacturing and development footprints to manage regulatory and political risk.

Korean biotech companies and government-backed initiatives, including K-Bio Global and KOTRA-led delegations, were highly visible throughout JPM week. These groups were not present for branding purposes. They were actively pursuing licensing, co-development, and manufacturing partnerships.

Innovation sourcing is becoming more geographically distributed, and global sponsors are increasingly open to assets originating outside traditional US and EU hubs.

Infectious Disease Strategies Are Being Refined, Not Abandoned

Gilead’s leadership used JPM to outline a more focused viral strategy, emphasizing selectivity and portfolio prioritization rather than broad expansion. This reflects a broader reassessment among large pharma companies, where infectious disease portfolios are now evaluated through the lens of sustainability and differentiated value, rather than pandemic-driven urgency.

FDA and CMS: Regulation as a Design Variable

Regulators featured prominently in strategic discussions at JPM 2026. The FDA signaled openness to accelerated pathways, greater flexibility around evidentiary requirements in select settings, and renewed efforts to make early-phase trials in the U.S. more competitive.

At the same time, Centers for Medicare & Medicaid Services used the conference as a direct engagement forum, emphasizing quality, access, interoperability, and administrative simplification. The message was consistent: regulatory and reimbursement considerations are no longer downstream risks — they are core design inputs for credible development programs.

What This Means For Clinical Development Partners

The collective signal from JPM 2026 is straightforward. Sponsors are looking for partners who can reduce execution risk early, support clean decision-making, and operate comfortably within regulatory and economic constraints. Agility still matters, but discipline matters more.

In this environment, CROs that combine scientific understanding with operational rigor are no longer viewed as service providers. They are strategic enablers.

Conclusion: Building Durable Growth After JPM 2026

The 2026 J.P. Morgan Healthcare Conference made one thing clear: the industry is entering a more disciplined and durable phase of growth. Strategic business development, platform-driven oncology, practical AI adoption, and a renewed focus on execution are reshaping how value is created across biopharma.

At Cromos Pharma, we see this shift not as a constraint, but as an opportunity. By combining scientific depth with operational rigor, and by focusing on feasibility, data quality, and execution from the earliest stages, we help our partners navigate complexity with confidence and make better decisions faster.

The tools, talent, and global connectivity available today are stronger than ever. What will differentiate success in this next phase is not ambition alone, but clarity, discipline, and alignment across development, regulation, and patient needs. By working collaboratively and staying grounded in real-world execution, the industry can continue to advance innovation while delivering meaningful impact for patients worldwide